Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02234427 · ClinicalTrials.gov registry record · Phase 4
Pharmacogenomics of Antiplatelet Response
A Phase 4 study of Atherosclerosis, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 4
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT02234427: Completed Phase 4 study of Atherosclerosis, sponsored by Johns Hopkins University.
NCT02234427 is a Phase 4 study of Atherosclerosis that has completed, run by Johns Hopkins University. The registered enrollment target is 34 participants, below the 1,065-participant average among 69 other Atherosclerosis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02234427, a Phase 4 study of Atherosclerosis, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial will examine with effect of 2-week aspirin therapy on platelet gene expression in persons at high-risk of developing heart attacks due to family history of early-onset coronary artery disease
Primary Outcome
Differences in platelet transcriptome before and after 2-week aspirin therapy The expression levels of genes before aspirin therapy was compared with the expression level of the genes after aspirin therapy. The expression levels were measured using the FPKM unit (Fragments Per Kilobase of transcript per Million mapped reads). The gene with the highest difference (pre vs. post) in FPKM is being reported with name in the units area and the actual difference in the number area
Conditions Studied
Interventions
- DRUG Aspirin
Study Locations (1)
Maryland
- Johns Hopkins School of Medicine - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2014-06 |
| Est. Completion | 2015-05 |
| Phase | Phase 4 |
What the finished NCT02234427 record still lists
NCT02234427 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 1,065-participant average among 69 other Atherosclerosis trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Atherosclerosis appearing as the primary indexed condition, and to 1 intervention - of which Aspirin is the first listed.
NCT02234427 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT02234427 about?
NCT02234427 is a clinical study titled "Pharmacogenomics of Antiplatelet Response". This clinical trial will examine with effect of 2-week aspirin therapy on platelet gene expression in persons at high-risk of developing heart attacks due to family history of early-onset coronary artery disease
What is the current status of trial NCT02234427?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 34 participants. The study started on 2014-06. Estimated completion is 2015-05.
What conditions does trial NCT02234427 study?
This clinical trial studies the following conditions: Atherosclerosis.
What interventions are being tested in trial NCT02234427?
The interventions under investigation include: Aspirin (DRUG).
Who is sponsoring clinical trial NCT02234427?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02234427 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atherosclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02234427's enrollment target sits among peer trials
34 62nd of 69 higher than 8 of 69 other Atherosclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atherosclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of Tirzepatide on Progression of Coronary Atherosclerosis Using MDCT
RECRUITING · Phase 4
-
Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes
RECRUITING · Phase 4
-
Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery
COMPLETED · Phase 4
-
Improving Cardiovascular Risk Prediction Using Hand Held Carotid Ultrasonography Study
COMPLETED · Phase 4
-
Testosterone Replacement in Older Men and Atherosclerosis Progression
COMPLETED · Phase 4
-
Randomized Trial of Imaging Versus Risk Factor-Based Therapy for Plaque Regression
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia